ABIVAX Société Anonyme
EPA:ABVX.PA
Overview | Financials
Company Name | ABIVAX Société Anonyme |
Symbol | ABVX.PA |
Currency | EUR |
Price | 9.45 |
Market Cap | 598,026,892 |
Dividend Yield | 0% |
52-week-range | 8.12 - 15.42 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Marc M. P. de Garidel M.B.A. |
Website | https://www.abivax.com |
An error occurred while fetching data.
About ABIVAX Société Anonyme
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD